CCM
MRTX

CAAS Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

CAAS Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-115,829
Closed -$19.8M – 1359
2021
Q1 		$19.8M Buy
+115,829
New +$22.9M 0.21% 108
2020
Q3 		– Sell
-257,928
Closed -$29.4M – 635
2020
Q2 		$29.4M Buy
+257,928
New +$25M 0.97% 27

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAAS Capital Management's MRTX Position: Q2 2021 in Review

CAAS Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 115,829 shares — an estimated $19.8M sold.

CAAS Capital Management first reported a position in MRTX in Q2 2020 and held it in 2 quarters. The position peaked at $29.4M in Q2 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • CAAS Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 115,829 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $19.8M.
  • CAAS Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $29.4M in Q2 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.